Clovis Oncology, Inc. (CLVS)
| Market Cap | 119.30M |
| Revenue (ttm) | 144.95M |
| Net Income (ttm) | -258.42M |
| Shares Out | 143.88M |
| EPS (ttm) | -2.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,577,296 |
| Open | 0.800 |
| Previous Close | 0.782 |
| Day's Range | 0.761 - 0.860 |
| 52-Week Range | 0.700 - 7.240 |
| Beta | 1.67 |
| Analysts | Sell |
| Price Target | 3.06 (+269.0%) |
| Earnings Date | May 4, 2022 |
About CLVS
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal canc...
Financial Performance
In 2021, CLVS's revenue was $148.76 million, a decrease of -9.58% compared to the previous year's $164.52 million. Losses were -$264.52 million, -28.35% less than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CLVS stock is "Sell." The 12-month stock price forecast is 3.06, which is an increase of 269.03% from the latest price.
News
2 Biotech Stocks That Could Go Parabolic
These gems are hiding in a sector that has been pummeled so far this year.
Why Clovis Oncology Stock Was Plummeting This Week
Investors bailed from the company after a quarterly results and operational update.
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
Clovis (CLVS) Q1 Loss Wider than Expected, Revenues Miss
Clovis (CLVS) incurs wider-than-estimated loss for first-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Clovis Oncology (CLVS) Reports Q1 Loss, Lags Revenue Estimates
Clovis (CLVS) delivered earnings and revenue surprises of -2.33% and 7.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Clovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
Why Clovis Oncology Stock Fell 10.5% on Monday
Clovis' shares dropped early in the day then rallied.
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022
Best Penny Stocks to Watch After the Stock Market Takes a Bear Turn
Can these penny stocks continue to climb after a bearish trading day? The post Best Penny Stocks to Watch After the Stock Market Takes a Bear Turn appeared first on Penny Stocks to Buy, Picks, News and ...
Clovis (CLVS) Up 24% on Upbeat Data From Ovarian Cancer Study
Clovis Oncology's (CLVS) stock price rises after it reports favorable data from a late-stage study on Rubraca as the first-line maintenance treatment of ovarian cancer.
Trading Penny Stocks & What You Need to Know in April
What you need to know about trading penny stocks in April The post Trading Penny Stocks & What You Need to Know in April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks...
Top Penny Stocks To Buy Under $5? 4 Short Squeeze Stocks To Watch Now
Short squeeze stocks to watch in April The post Top Penny Stocks To Buy Under $5? 4 Short Squeeze Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Clovis Oncology Stock Skyrocketed 80% This Week
Positive data regarding its lead drug boosted the company's shares.
Clovis Oncology News: Why CLVS Stock Is Roaring Higher Today
Clovis Oncology (CLVS) stock is in the news Thursday as shares rocket higher thanks to positive data from a recent clinical trial. The post Clovis Oncology News: Why CLVS Stock Is Roaring Higher Today a...
Clovis Oncology's Rubraca Significantly Improves PFS In Ovarian Cancer Regardless Of Biomarker Status
Clovis Oncology Inc (NASDAQ: CLVS) announced positive topline data from the monotherapy arm of Phase 3 ATHENA-MONO trial of Rubraca (Rucaparib) as first-line maintenance treatment in ovarian cancer. Rub...
Trading Penny Stocks? Top Stock Market News for March 31st, 2022
Here's what you need to know about trading penny stocks on March 31st The post Trading Penny Stocks? Top Stock Market News for March 31st, 2022 appeared first on Penny Stocks to Buy, Picks, News and Inf...
Why Clovis Oncology Stock Is Soaring Today
Clovis Oncology Inc (NASDAQ: CLVS) is trading higher Thursday morning after the company announced data from the monotherapy arm of the ATHENA trial achieved the primary endpoint of significantly improve...
Clovis Oncology to seek FDA approval for ovarian cancer drug as a maintenance therapy
Shares of Clovis Oncology Inc. CLVS, -3.51% soared 40.0% in premarket trading on Thursday after the company said its drug, Rubraca, improved survival when used as a maintenance treatment for women with ...
Clovis Oncology's Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Tre...
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology's Rubraca® (Rucaparib) Significantly Improves PFS in First-line Maintenance Treatment in Women with Ovarian Cancer ...
Why Is Clovis (CLVS) Down 14.8% Since Last Earnings Report?
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?
Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-22...
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286
Hot Penny Stocks to Watch Next Week? 3 For Your List
Which penny stocks are on your watchlist for next week? The post Hot Penny Stocks to Watch Next Week?